Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2007 by Shahid Beheshti Medical University.
Recruitment status was  Recruiting
Information provided by:
Shahid Beheshti Medical University
ClinicalTrials.gov Identifier:
First received: August 31, 2006
Last updated: February 26, 2007
Last verified: February 2007

In active phase of thyroid eye disease some patients have obvious upper lid retraction , and sometimes exposure keratopathy .To date there is not any standard treatment for this situation . We are going to compare the natural course of the upper lid retraction with injection of botulinum toxin A injection to upper lid percutaneously.

Condition Intervention Phase
Eye Diseases
Drug: Botulinum toxin A injection
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Shahid Beheshti Medical University:

Estimated Enrollment: 50
Study Start Date: May 2005
Estimated Study Completion Date: February 2007

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • all the patients wiht oper lid retraction in active phase of thyroid ophthalmopathy

Exclusion Criteria:

  • patients in non active phase
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00370734

Contact: Babak Babsharif, MD +98 21 22585952 labbafi@hotmail.com

Iran, Islamic Republic of
Babak Babsharif, MD Recruiting
Tehran, Iran, Islamic Republic of, 16666
Contact: Babak Babsharif, MD    +98 21 22585952    labbafi@hotmail.com   
Sponsors and Collaborators
Shahid Beheshti Medical University
Principal Investigator: Babak Babsharif, MD Ophthalmic Research Center of Shaheed Beheshti Medical University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00370734     History of Changes
Other Study ID Numbers: 8375
Study First Received: August 31, 2006
Last Updated: February 26, 2007
Health Authority: Iran: Ethics Committee

Keywords provided by Shahid Beheshti Medical University:
botulinum toxin
thyroid eye disease
lid retraction

Additional relevant MeSH terms:
Eye Diseases
Botulinum Toxins
Botulinum Toxins, Type A
Anti-Dyskinesia Agents
Central Nervous System Agents
Neuromuscular Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on March 26, 2015